Subscribe to NRx Newsletter

Press Releases

Aug. 10, 2021
NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021

NRx Advancing Investigational Medicines for Critical COVID-19 and Other Respiratory Conditions, Vaccine to Prevent COVID-19 and Breakthrough Drug for Suicidal Depression and PTSD RADNOR, Pa., Aug. 10, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will […]

Read More
Aug. 9, 2021
NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia

Dose-Confirmatory Trial Follows Successful Phase 2a Trial Preclinical and Early Human Data Indicate BriLife™ May Confer Enhanced Immunity Against Delta variant RADNOR, Pa., Aug. 9, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID-19 in the Nation of Georgia.  The vaccine […]

Read More
Aug. 4, 2021
NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions

ZYESAMI™ (aviptadil) was awarded Fast Track Designation by the U.S. Food and Drug Administration for the Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome Associated with COVID-19 Potential Applications for Dry Powder Formulation of ZYESAMI™ Extend to Many Pulmonary Conditions Beyond COVID-19 RADNOR, Pa., Aug. 4, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed […]

Read More
Jul. 27, 2021
NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia

More than One Thousand New Cases of COVID-19 Diagnosed Every Day in Georgia, With Increasing Detection of the Delta Variant Association of Georgian Physicians Unanimously Supports Regulatory Decision Training of Georgian Doctors in use of ZYESAMI™ (aviptadil) to Begin Within 24 Hours RADNOR, Pa., July 27, 2021 /PRNewswire/ — NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global […]

Read More
Jul. 19, 2021
NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent “Cytokine Storm” in Patients with COVID-19

Sudden Rise in Inflammatory Cytokines (IL-6) Associated with Death in COVID-19 and Other Forms of Acute Respiratory Distress Syndrome Data from Randomized Phase 2b/3 Trial Shows Patients Treated with ZYESAMI™ are Significantly Less Likely to Experience IL-6 Cytokine Rise, and Have Improved Survival and Recovery from Respiratory Failure, Compared to Patients Receiving Placebo Data Have […]

Read More
Jun. 1, 2021
NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure

– ZYESAMI™ is the First Investigational Medicine to Show Efficacy in a Randomized, Double-Blind, Multicenter Trial, Achieving More Instances of Recovery in Critically Ill COVID-19 Patients with Respiratory Failure, Compared to Placebo – ZYESAMI™ Demonstrated a Significant Treatment Advantage and Shortened Hospitalization in Patients Already Treated with All Approved Therapies for Critical COVID-19 – Filing […]

Read More
Apr. 26, 2021
Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

PR Newswire RADNOR, Pa., April 26, 2021 /PRNewswire/ — Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO) (www.clinicaltrials.gov NCT04843761), will study ZYESAMI to treat severely ill COVID-19 patients. The […]

Read More